Form 4: Revolution Medicines Director Frank Clyburn Reports Significant Equity Grant

Revolution Medicines, Inc. Director Frank Clyburn reported the acquisition of 2,806 shares of common stock and 10,337 stock options on June 26, 2025, increasing his beneficial ownership in the company.

Summary

• Frank Clyburn, a Director of Revolution Medicines, Inc. (RVMD), acquired 2,806 shares of common stock on June 26, 2025, at a price of $0, indicating a grant or award.
• Clyburn also acquired 10,337 stock options on June 26, 2025, with an exercise price of $37.48 per share and an expiration date of June 26, 2035.
• Following these transactions, Clyburn beneficially owns a total of 9,738 shares of common stock, which includes 8,005 Restricted Stock Units.
• He also beneficially owns 10,337 stock options.
• The acquired stock options are subject to vesting on the earlier of the first anniversary of June 26, 2025, or immediately prior to the Annual Meeting following the grant date, contingent on Clyburn remaining a Service Provider through the vesting date.

Sentiment

Score: 7

Explanation: The filing indicates an increase in insider ownership through equity grants, which is generally viewed positively as it aligns management/director interests with shareholders. It's a routine compensation event, not a major strategic announcement, hence a moderate positive score.

Positives

• Director Frank Clyburn's acquisition of additional shares and stock options through an equity grant aligns his financial interests with those of the company's shareholders.
• The grant of equity compensation to a key director indicates a commitment to retention and incentivization for long-term performance.

Future Outlook

The vesting schedule for the acquired stock options indicates a future milestone for the Director's equity, contingent on continued service, aligning his long-term interests with the company's performance and strategic objectives.

Industry Context

This Form 4 filing reflects a routine equity grant to a director, a common practice in the biotechnology and pharmaceutical industry to incentivize and retain key leadership. Such grants are standard components of executive and director compensation packages, aligning their financial interests with long-term shareholder value creation.

Comparison to Industry Standards

• The equity grant to Director Frank Clyburn, comprising both common stock and stock options, is consistent with typical compensation structures for non-employee directors in the biopharmaceutical sector.
• Similar grants are observed across peers in the biotechnology industry, such as Moderna (MRNA), BioNTech (BNTX), or Gilead Sciences (GILD), for their board members, aiming to foster long-term commitment and performance alignment.
• The vesting schedule tied to continued service is a standard industry practice for such equity awards.

Stakeholder Impact

• Shareholders: Increased alignment of a director's interests with shareholder value due to increased equity ownership.

Next Steps

• The acquired stock options will vest on the earlier of June 26, 2026 (first anniversary of grant) or immediately prior to the Annual Meeting following the grant date, subject to continued service.

Key Dates

Keywords

Revolution Medicines, RVMD, Frank Clyburn, SEC Form 4, Insider Transaction, Stock Options, Restricted Stock Units, Director Compensation, Equity Grant, Beneficial Ownership